ARA-290 (Cibinetide): The EPO-Derived Peptide That Targets Nerve Repair Without the Blood Risk
ARA-290 is an EPO-derived peptide with promising but unconfirmed Phase 2 signals in small fibre neuropathy. Mechanistically rational, consistently safe in short trials.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-06-17An EPO-derived peptide engineered to activate the innate repair receptor without EPO's blood effects; three small placebo-controlled Phase 2 trials in small-fibre neuropathy reported improvements (incl. objective corneal nerve-fibre regrowth) with a clean short-term safety record, but development stalled with no completed Phase 3, a negative diabetic-macular-edema result, and no approval anywhere.
Well-characterised innate-repair-receptor (EPOR/beta-common heteromer) selectivity, shown by loss of effect in beta-common-receptor knockouts; the non-erythropoietic design (no haematocrit rise) is confirmed in humans.
Moderate and mechanistically supportive across colitis, islet-transplant, autoimmune-neuritis and Alzheimer's models, but animal/in-vitro only.
Three small placebo-controlled Phase 2 trials in neuropathy were positive (incl. objective corneal nerve-fibre density), but small and largely company-sponsored; a diabetic-macular-edema Phase 2 was negative, and no Phase 3 was completed.
Encouraging neuropathy signals including objective nerve regrowth, but unconfirmed and non-generalising (the macular-edema indication was negative).
Partial but reassuring short-term: well tolerated up to 12 weeks, no serious adverse events, no anti-drug antibodies, and (unlike EPO) no haematocrit rise; long-term/large-population safety is unestablished.
Reached Phase 2 with FDA Orphan Drug and Fast Track designations, but no Phase 3 was completed and development has stalled (sponsor inactive; no active registered trials as of 2026).
Moderate: consistent Phase 2 neuropathy signals, but unconfirmed by a Phase 3 and not generalising to every indication.
Investigational and unapproved anywhere (Orphan Drug / Fast Track are designations, not approval); realistic supply is grey-market.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
An EPO-derived, non-erythropoietic peptide; three small placebo-controlled Phase 2 trials in small-fibre neuropathy reported improvements (including objective nerve-fibre regrowth), but development stalled with no completed Phase 3.
Safety snapshot
Short-term trial safety (up to ~12 weeks) was reassuring, with no rise in haematocrit; long-term and large-population safety is unestablished, and no human data address infection, cancer or pregnancy.
Regulatory & legality
Investigational and unapproved anywhere (Orphan Drug/Fast Track are designations, not approval); the only practical supply is grey-market.
Where claims can exceed the evidence
Early Phase 2 signals are unconfirmed and did not generalise — a diabetic-macular-edema trial was negative — so durable clinical benefit is not established.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
ARA-290, also known as cibinetide, is one of the more scientifically interesting peptides circulating in self-experimentation circles. It was engineered to capture the tissue-protective, anti-inflammatory side of erythropoietin (EPO) while leaving behind the blood-thickening effects that make EPO risky. On paper, that is a clever bit of pharmacology. In practice, it has a real but early-stage human evidence base: a handful of small placebo-controlled trials in nerve disease, an excellent short-term safety record, and several promising signals — none of which have ever been confirmed in a large Phase 3 study.
If you are weighing ARA-290, the honest summary is this: the mechanism is well worked out, the safety in short trials looks clean, and the neuropathy data are genuinely encouraging — but the development programme stalled, the sponsor appears inactive, and nothing sold online is a verified pharmaceutical product. This article walks through what the published research actually shows, and where it stops.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
BPC-157: What the Evidence Actually Shows
A clear-eyed look at BPC-157: a peptide with promising rodent healing data, almost no human evidence, and serious regulatory and sourcing caveats.
KPV: The alpha-MSH Tripeptide With a Strong Preclinical Case and No Human Trials
KPV is an alpha-MSH-derived anti-inflammatory tripeptide with solid animal and cell-based evidence, mostly in gut inflammation, but zero published human trials.
LL-37: The Body's Own Antibiotic — What the Evidence Actually Shows
LL-37 is the human cathelicidin peptide with rich antimicrobial and wound-healing biology, but solid human data exists only for topical wound use — and it's dual-edged.
TB-500 (Thymosin Beta-4): What the Evidence Actually Shows
TB-500's actin-repair biology is solid in animals, but human evidence exists only for topical eye drops — and injectable use rests on anecdote alone.